Clebopride malate, a dopamine antagonist, is therapeutically used for the treatment of peptic ulcer. This drug has potent antidopaminergic activity that causes acute dystonic reaction, parkinsonism and tardive dyskinesia as adverse effects. After cessation of clebopride malate limb dyskinesia disappeared rapidly and respiratory dyskinesia markedly decreased[3]. Clebopride is a class of antidopaminergic gastrointestinal prokinetic. Clebopride at 10 microM significantly decreased the Vmax of phase 0 depolarization and significantly prolonged the action potential duration at 90% repolarization (APD90), whereas the action potential duration at 50% repolarization (APD50) was not prolonged. For hERG (human ether-a-go-go-related gene) potassium channel currents, the IC50 value was 0.62 ± 0.30 microM. Clebopride was found to have no effect on sodium channel currents[4]. Clebopride (0.5, 1.0 and 2.0 mg/kg) promoted significant analgesia in the tail-flick and hot-plate tests and against abdominal constrictions produced by acetic acid or acetylcholine[5]. The adjunct use of Clebopride in PEG (polyethylene glycol electrolyte) solution for colonoscopy preparations tends to increase the acceptability, tolerability, and efficacy. The presence of borborygmus was significantly lower in the Clebopride group[6].
搜索
